Core Viewpoint - The article highlights the significant divergence in performance among various sectors in the Chinese stock market during Q4 2025, with technology and growth sectors like AI computing and semiconductors outperforming traditional sectors such as real estate and pharmaceuticals [1][2][4]. Summary by Sections Market Performance - In Q4 2025, the Shanghai Composite Index rose by 2.22%, while the CSI 300 Index fell by 0.23%, and the ChiNext Index decreased by 1.08%. The Hang Seng Index dropped by 4.56%, and the Hang Seng China Enterprises Index fell by 6.72% [1]. Fund Manager Strategies - Star fund managers like Fu Pengbo and Li Xiaoxing achieved significant excess returns, with Fu's Ruiyuan Growth Value Fund and Li's Yinhua Small Cap Select both rising over 60% in 2025, driven by heavy investments in AI computing and semiconductors [1][2]. - Balanced allocation funds, such as Zhu Shaoxing's Fuguo Tianhui Select Growth A, showed stable performance with over 20% annual growth, benefiting from diversified holdings across multiple sectors [2][12]. Technology Growth Focus - Funds focusing on technology growth, like those managed by Fu Pengbo and Xie Zhiyu, saw rewards for their strategies, with increased allocations to data center cooling, storage, and computing-related companies [4][5]. - Li Xiaoxing emphasized AI as a key investment theme, with a strong focus on semiconductor companies, indicating a shift towards domestic advanced processes and military-civilian integration opportunities [6]. Traditional Value Sector - Fund managers like Zhang Kun and Liu Yanhun maintained positions in traditional sectors like consumer goods and pharmaceuticals, facing significant net value pressure in Q4 2025. Liu's fund saw a decline of 5.85% in Q4, while Zhang's fund remained stable but adjusted sector allocations [8][10]. - Despite challenges, the pharmaceutical sector showed signs of improvement due to policy changes and innovation, with opportunities emerging in innovative drug chains and medical devices [9][10]. Consensus Among Fund Managers - Despite differing investment styles, fund managers shared common views on the impact of "anti-involution" policies on corporate fundamentals and the relative attractiveness of equity assets in the current market environment [16][17]. - The importance of stock selection has increased significantly, with a focus on identifying core companies with competitive advantages in both growth and value sectors [17].

Group 1: Lier Chemical - Lier Chemical is a global leader in chlorinated pyridine herbicides and a leading company in glyphosate and refined glyphosate, with products sold in over 30 countries and regions [1] - The core growth logic is driven by the accelerated ban on glyphosate, with the market size for glyphosate expected to grow from 3 billion yuan in 2020 to 8 billion yuan in 2025, representing a compound annual growth rate (CAGR) of 22% [1] - Lier Chemical is the second company globally and the first in China to master the industrialization of cyanopyridine chlorination technology, with a total production capacity exceeding 50,000 tons per year, achieving full production and sales [1] - The company has a market share of over 70% globally, with more than 80% of its sales coming from long-term supply agreements, and both product categories are currently in a price increase cycle [1] - The company has seen its performance improve by over 100% for three consecutive quarters [1] Group 2: Shandong Heda - Shandong Heda is the absolute leader in cellulose ether in China and a core supplier of plant capsules globally, with raw materials sourced from cotton, wood, and bamboo [2] - The focus is on medical-grade and food-grade cellulose ether, with profit margins reaching 25% to over 35%, particularly for medical-grade cellulose ether, which sees annual price increases and growing margins [2] - The company has established long-term supply agreements with major domestic pharmaceutical companies such as Heng Rui and Shi Yao, as well as international firms like Pfizer, Novartis, and Bayer, supplying 15 out of the top 20 global pharmaceutical companies [2] - The global capsule market is over 30 billion yuan, with the share of plant capsules expected to increase from 15% in 2020 to 30% in 2025, reflecting a CAGR of over 20% as a clear trend to replace gelatin capsules [2] - Shandong Heda has a domestic production capacity of 20 billion capsules per year, with a $500 million investment in the U.S. to build a project with the same capacity, expected to be operational by Q3 2026 [2]

Core Viewpoint - Heng Rui Medicine's stock price has shown a decline of 3.07% year-to-date, with a notable drop of 6.75% over the past 60 days, indicating potential challenges in market performance [2]. Company Overview - Jiangsu Heng Rui Medicine Co., Ltd. is primarily engaged in the research, production, and sales of pharmaceuticals, focusing on oncology, including kinase inhibitors, antibody-drug conjugates (ADC), tumor immunology, hormone receptor regulation, DNA repair, and epigenetics [2]. - The company's product portfolio includes anti-tumor drugs, analgesics, and contrast agents, applicable in various medical fields such as autoimmune diseases, metabolic diseases, cardiovascular diseases, infectious diseases, respiratory diseases, hematological diseases, pain management, neurological diseases, ophthalmology, and nephrology [2]. - The main revenue sources for Heng Rui Medicine are product sales (86.88%), licensing income (12.63%), and other income (0.49%) [2]. Financial Performance - As of September 30, Heng Rui Medicine reported a total revenue of 23.188 billion yuan, reflecting a year-on-year growth of 14.85%, and a net profit attributable to shareholders of 5.751 billion yuan, which is a 24.50% increase compared to the previous year [3]. - The company has distributed a total of 9.303 billion yuan in dividends since its A-share listing, with 3.568 billion yuan distributed over the past three years [4]. Shareholder Information - As of September 30, the number of shareholders for Heng Rui Medicine reached 397,300, an increase of 8.94% from the previous period, while the average circulating shares per person decreased by 8.21% to 16,058 shares [3]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited holds 487 million shares, a decrease of 48.1792 million shares from the previous period [4].

全球脑机接口玩家奋楫争先，产业化落地谱写投资蓝图 20260128 摘要 创新药领域，减肥、小核酸及 2L 疗法值得关注。减肥和 IO 赛道市场规 模达千亿美元级别，具弹性机会。小核酸赛道也因高景气度备受关注。 全年维度来看，医药板块值得重点关注。 脑机接口商业化处于起步阶段，是 2026 年投资主线。植入式临床进展 迅速，心伟医疗、爱鹏医疗和乐普医疗安全性具优势。非侵入式方面， 翔宇、迈兰德、创新医疗和诚益通等公司靠前。 政策支持对脑机接口行业发展起到重要引领作用，2025 年推出发展目 标与产业规划蓝图，确立收费项目立项，提高公立医院购买积极性，为 未来纳入医保铺平道路。 脑机接口产业链核心技术壁垒集中于中上游，包括硬件（电极、芯片）、 手术机器人及算法处理等。国产替代进程加速，美好医疗率先卡位上游 并开始代工侵入型电极。 Neuralink 需定制 ASIC 芯片，因通用芯片无法在处理上千通道信号的 同时控制功耗。其关键部分是模拟前端，需实现微弱神经信号的放大、 滤波和数字化。 Q&A 目前医药板块的投资机会主要集中在哪些方向？ 当前医药板块的投资机会主要集中在创新药及其相关产业链上。尤其是一些龙 头企 ...

Summary of Key Points from the Conference Call Industry Overview - The conference call focuses on the **China Healthcare** sector, specifically the **pharmaceutical industry** in China, with insights into various companies and their performance outlooks for 2025 and 2026 [1][2][6]. Core Companies Discussed 1. **Jiangsu Hengrui Pharmaceuticals (600276.SS)** - Expected product sales growth of **12% YoY** in 2025, driven by **~25% growth** in innovative drug sales [10]. - Anticipated net profit growth faster than revenue due to higher contributions from business development (BD) income and lower operating expenses [10]. - Projected to achieve **25%+ growth** in innovative drug sales in 2026, supported by **10 new NRDL entries** [36]. 2. **Hansoh Pharmaceutical Group Co Ltd (3692.HK)** - Total revenue growth forecasted at **20%** in 2025, with **17%** growth in product sales [10]. - Net profit expected to grow at a slower pace due to high base effects and ongoing R&D investments [10]. 3. **3SBio (1530.HK)** - Revenue projected at **Rmb19bn** in 2025, with a slight decline in product sales [10]. - Anticipated modest growth in 2026, with new products ramping up [10]. 4. **CSPC Pharmaceutical Group (1093.HK)** - Projected total revenue decline of **7% YoY** in 2025, with a **10% drop** in finished drug sales [10]. - Expected net profit growth of **17%** due to BD income [10]. 5. **Sino Biopharmaceutical (1177.HK)** - Forecasted total revenue growth of **15%** in 2025, driven by biosimilar growth [11]. - Projected net profit growth of **73%**, largely due to higher dividend payments from Sinovac [12]. 6. **Fosun Pharmaceutical (2196.HK)** - Expected flat total revenue in 2025, with a projected **20% growth** in net profit due to operational savings [12]. 7. **China Medical System (0867.HK)** - Revenue growth of **10%** expected in 2025, with a focus on innovative drugs [12]. - Plans to spin off its dermatology subsidiary, Dermavon, to unlock equity value [49]. Key Insights and Trends - **Globalization** remains a significant theme, with companies focusing on pipeline advancements and out-licensing deals to enhance revenue streams [2][8]. - The **China pharma sector** is experiencing a shift towards innovative drug development, with many companies investing heavily in R&D to mitigate the impact of pricing pressures and regulatory changes [49][67]. - **Out-licensing deal momentum** for China-originated assets is robust, indicating a healthy market for collaboration and partnerships [8]. Financial Projections - **Hengrui**: Projected **Rmb31.4bn** in revenue for 2025, with a **12.3% YoY** increase [16]. - **Hansoh**: Expected revenue of **Rmb14.7bn** in 2025, with a **20.1%** growth rate [16]. - **3SBio**: Revenue forecasted at **Rmb19bn** in 2025, with a significant increase in net profit [16]. - **CSPC**: Anticipated revenue of **Rmb26.997bn**, reflecting a **-6.9%** change [16]. - **Sino Biopharma**: Expected revenue of **Rmb33.333bn**, with a **15.5%** growth [16]. Risks and Considerations - Companies face **regulatory pressures** and pricing challenges, particularly from the **Volume-Based Procurement (VBP)** policies [49][63]. - The potential for **pipeline setbacks** and delays in new product launches could impact growth trajectories [63][67]. - The **spinoff of Dermavon** may be perceived negatively by some investors, but it is expected to enhance the financial flexibility of China Medical System [50]. Conclusion The conference call highlighted a positive outlook for the China pharmaceutical industry, driven by innovative drug sales and strategic partnerships. However, companies must navigate regulatory challenges and market pressures to sustain growth.

Core Viewpoint - The Shanghai 180 ETF Index Fund (530280) has shown a positive performance with a recent increase of 0.71% over the past week and a 14.83% rise over the last six months, indicating strong market interest and potential investment opportunities [1][2]. Performance Summary - As of January 28, 2026, the Shanghai 180 ETF Index Fund has achieved a maximum monthly return of 9.13% since its inception, with the longest consecutive monthly gain being 6 months and a total gain of 22.51% during that period [2]. - The fund has a historical average monthly return of 3.08%, with a monthly profit percentage of 72.73% and a monthly profit probability of 74.89% [2]. - The fund has maintained a 100% probability of profit over a one-year holding period since inception, with an annualized return exceeding the benchmark by 2.31% [2]. Risk and Fee Analysis - The maximum drawdown for the fund this year is 1.30%, with a relative benchmark drawdown of 0.06%, indicating a relatively stable performance [3]. - The management fee for the fund is 0.15%, and the custody fee is 0.05%, which are among the lowest in comparable funds [3]. - The tracking error over the past three months is 0.018%, demonstrating high tracking precision compared to similar funds [3]. Index Composition - The Shanghai 180 Index consists of 180 securities selected from the Shanghai market, reflecting the overall performance of core listed companies [3]. - As of December 31, 2025, the top ten weighted stocks in the index include Kweichow Moutai, Zijin Mining, and China Ping An, collectively accounting for 25.29% of the index [3].

我们不是资讯的搬运工 而是有态度的发现者 万和财富早班车 2026年1月29日 | 品种 | 收盘 | 涨跌幅 | 品种 | 收盘 | 涨跌幅 | | --- | --- | --- | --- | --- | --- | | 上证指数 4151.24 | | 0.27% | 上证当月连续 | 3065.6 | -0.03% | | 深证成指 14342.89 | | 0.09% | 沪深当月连续 | 4727.8 | 0.08% | | 创业板指 | 3323.56 | -0.57% | 恒生期货指数 | 35848.43 | 2.66% | 宏观消息汇总 1.国家药监局: 《采用脑机接口技术的医疗器械范式设计与应 用规范运动功能重建》等2项医疗器械行业标准立项。 2国家能源局:截至2025年底,全国累计太阳能发电装机容量 12亿千瓦，同比增长35.4%。 3.国务院国资委：大力推进战略性、专业化重组和高质量并购。 2.盈新发展(000620)：拟5.2亿元收购长兴半导体60%股权，切入 存储芯片领域。 3.中牧股份(600195)：预计2025年度实现归属于上市公司股东的 净利润1.49亿元到1.92亿元 ...

Core Viewpoint - The upcoming regulatory changes in traditional Chinese medicine (TCM) are perceived as a necessary industry "slimming down," primarily targeting "zombie approvals" that have little to no market presence, rather than posing a significant threat to the overall market supply [1][3]. Regulatory Changes - The new regulations, effective from July 1, 2026, stipulate that if any safety information such as contraindications or adverse reactions remains "unclear" in the product's instructions after three years, the drug will not be eligible for re-registration [3][10]. - Most of the approvals expected to be eliminated are considered "zombie approvals," which are low-value, highly homogeneous products with negligible or zero market sales [3][4]. Industry Response - Industry insiders express that the costs associated with updating the required safety data are manageable, with estimates ranging from several thousand to tens of thousands of yuan per approval [4][7]. - Companies are likely to abandon these "zombie approvals" voluntarily, as they represent ongoing liabilities without significant market impact [5][9]. Market Dynamics - The real concern for the industry lies in the ongoing centralized procurement of TCM and the upcoming adjustments to the national essential drug list, which will significantly influence the core profits and survival of companies [10][11]. - The centralized procurement process, set to include 90 products with a market scale of over 45 billion yuan, raises questions about the future pricing and competitiveness of TCM products [10][11]. Future Outlook - The regulatory timeline provides a lengthy window for companies to adapt, with many already completing re-registration for key products [6][8]. - The adjustments to the essential drug list are anticipated to be more impactful than the registration regulations, as they will determine which products can access the main hospital channels [10][11].

2025年四季度，市场波动有所加大，A股和港股在震荡中收官，结构性行情演绎至极致。Wind数据显示，去年四季度上证指数上涨2.22%，沪 深300指数下跌0.23%，创业板指下跌1.08%。此外，恒生指数下跌4.56%，恒生中国企业指数下跌6.72%。 主要指数表现平淡，但内部行业却冰火两重天。以AI算力、半导体为代表的科技成长板块高歌猛进，石油石化、国防军工、有色金属等行业 表现较好，而房地产、医药、计算机等行业表现相对承压。 随着公募基金2025年四季报披露完毕，傅鹏博、朱少醒、张坤、葛兰、谢治宇、李晓星、刘彦春等明星基金经理的持仓动向与后市展望浮出水 面。这种极致的市场风格，也映射出这些公募明星基金经理们截然不同的投资路径，这些分化直接体现在他们的净值曲线上。 Wind数据显示，锚定科技主线的基金在2025年四季度及2025年全年斩获显著超额收益。傅鹏博的睿远成长价值和李晓星的银华中小盘精选， 2025年全年上涨均超60%，大幅跑赢业绩比较基准。两者的共同特点是重仓AI算力、半导体等全年市场主线。 均衡配置型基金的表现也较为稳健。朱少醒的富国天惠精选成长A全年涨幅超20%，其分散在金融、消费、制造等多个 ...

Core Viewpoint - The market experienced increased volatility in Q4 2025, with A-shares and Hong Kong stocks showing mixed performance, while sectors like AI computing and semiconductors thrived, contrasting with weaker performances in real estate and pharmaceuticals [1] Group 1: Market Performance - The Shanghai Composite Index rose by 2.22% in Q4 2025, while the Hang Seng Index fell by 4.56% [1] - The technology growth sector, particularly AI computing and semiconductors, showed significant gains, while industries such as real estate and pharmaceuticals faced challenges [1] Group 2: Fund Manager Performance - Star fund managers like Fu Pengbo and Li Xiaoxing achieved over 60% returns in 2025, focusing on AI computing and semiconductors [2] - Balanced allocation funds, such as Zhu Shaoxing's, demonstrated stability with a 20% annual return, benefiting from diversified investments across various sectors [3][14] Group 3: Investment Strategies - Fu Pengbo's fund increased its allocation to data center cooling and computing-related companies, with a top ten stock concentration of 70.38% [5] - Li Xiaoxing emphasized AI hardware innovation and semiconductor investments, with a focus on domestic advancements in the semiconductor industry [6] Group 4: Traditional Value Investments - Fund managers like Zhang Kun and Liu Yanhun maintained positions in traditional sectors like consumer goods and pharmaceuticals, despite facing net value pressures [8][12] - Liu Yanhun's fund experienced a 5.85% decline in Q4, reflecting the challenges faced by traditional value sectors [12] Group 5: Policy and Market Outlook - Fund managers noted the impact of "anti-involution" policies on corporate fundamentals, suggesting a shift towards supply-side optimization [17] - Despite market rebounds, equity assets are still viewed as attractive, with a focus on high-quality listed companies as scarce income-generating assets [18]